Patents by Inventor Colin Peter Sambrook Smith

Colin Peter Sambrook Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GPCR Agonists
    Publication number: 20090325924
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
    Type: Application
    Filed: June 29, 2006
    Publication date: December 31, 2009
    Inventors: Stuart Edward, Graham John Dawson, Matthew Colin Thor Fyfe Oxford, Lisa Sarah Bertram, William Gattrell, Revathy Perpetua Jeevaratnam, John Keily, Neela Sumit Mistry, Martin James Procter, Chrystelle Marie Rasamison, Philip John Rushworth, Colin Peter Sambrook-Smith, David French Stonehouse
  • Gpcr Agonists
    Publication number: 20090221644
    Abstract: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.
    Type: Application
    Filed: June 29, 2006
    Publication date: September 3, 2009
    Inventors: Stuart Edward Bradley, Matthew Colin Thor Fyfe, Lisa Sarah Bertram, William Gattrell, Martin James Procter, Chrystelle Marie Rasamison, Colin Peter Sambrook-Smith, Vilasben Kanji Shah, David French Stonehouse, Simon Andrew Swain, Gerard Hugh Thomas
  • N-substituted benzimidazolyl c-Kit inhibitors
    Patent number: 7521448
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: April 21, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Joshua Bolger, Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Mulvihill, Li Qiu, Colin Peter Sambrook Smith, Yingchaun Sun, Graham Michael Wynne, Tao Zhang
  • N-Substituted Imidazopyridine c-Kit Inhibitors
    Publication number: 20090062275
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Application
    Filed: September 12, 2008
    Publication date: March 5, 2009
    Inventors: Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Radoslaw Laufer, An-Hu Li, Li Qiu, Colin Peter Sambrook Smith, Tao Zhang
  • N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
    Patent number: 7485658
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: February 3, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Joshua Bolger, Arlindo L. Castelhano, Andrew Phillip Crew, Radoslaw Laufer, An-Hu Li, Colin Peter Sambrook Smith, Yingchuan Sun
  • Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
    Publication number: 20090023703
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
    Type: Application
    Filed: July 2, 2008
    Publication date: January 22, 2009
    Inventors: Stuart Edward Bradley, Thomas Martin Krulle, Peter John Murray, Martin James Procter, Robert John Rowley, Colin Peter Sambrook Smith, Gerard Hugh Thomas
  • Substituted pyrrolo[2.3-B]pyridines
    Patent number: 7465726
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: December 16, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, William Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo G. Steinig, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth (‘Ken’) Foreman, Qinghua (‘Felix’) Weng, Kathryn Stolz
  • N3-substituted imidazopyridine c-Kit inhibitors
    Patent number: 7442709
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of cancer.
    Type: Grant
    Filed: August 16, 2004
    Date of Patent: October 28, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Arlindo L. Castelhano, Andrew Phillip Crew, Han-Qing Dong, Radoslaw Laufer, An-Hu Li, Li Qiu, Colin Peter Sambrook Smith, Tao Zhang
  • N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library
    Patent number: 7419995
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors. Combinatorial libraries composed of compounds represented by Formula (I) or benzimidazole compounds represented by Formula (II): are useful in providing compounds to assay for such therapeutically useful compounds.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: September 2, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Andrew Philip Crew, Matthew Cox, Radoslaw Laufer, Neil Anthony Pegg, Colin Peter Sambrook Smith, Yingchuan Sun, Robin David Wilkes, Jonathan Williams
  • Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
    Patent number: 7405210
    Abstract: Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: July 29, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Stuart Edward Bradley, Thomas Martin Krulle, Peter John Murray, Martin James Procter, Robert John Rowley, Colin Peter Sambrook Smith, Gerard Hugh Thomas
  • Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
    Publication number: 20060211678
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Application
    Filed: August 1, 2005
    Publication date: September 21, 2006
    Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, Wiliam Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo Steing, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth Foreman, Qinghua Weng, Kathryn Stolz